Predict your next investment

Asset/Investment Management
ambriacap.com

See what CB Insights has to offer

Investments

5

Portfolio Exits

1

About Ambria Capital

Ambria Capital invests into emerging public and private companies in the agriculture, consumer, healthcare, and technology industries.

Ambria Capital Headquarter Location

San Juan,

Puerto Rico

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ambria Capital News

08:00 EDT Phyto Partners Launches Neurowellness-Focused Venture Capital Fund

Apr 19, 2022

News provided by Share this article Share this article BOCA RATON, Fla., April 19, 2022 /PRNewswire/ - Phyto Partners, LLC ("Phyto"), a top venture capital fund, is launching its fourth private equity fund – Phyto IV, LP – focused on businesses operating in and around neurowellness and brain health and the use of psychedelic compounds for the improvement of mental well-being. Managing Partner Larry Schnurmacher (CNW Group/Phyto Partners) Managing Partner Cody Shandraw (CNW Group/Phyto Partners) Phyto Partners has partnered with Ambria Capital, LLC ("Ambria"), for the management of Phyto IV. Founded in 2019 by a team of investment professionals with decades of success in the healthcare and technology markets, Ambria combines a comprehensive analytical approach with an unparalleled network of contacts to connect industry leaders with market opportunities. Managing Partners Larry Schnurmacher and Cody Shandraw "Our research indicates that we are on the verge of a neurowellness brain health megatrend that will include the resurgence of Psychotropics/Psychedelics as a Medicine and for all around mindfulness," said Larry Schnurmacher, Managing Partner. "The neurowellness sector has become one of the fastest-growing and largest markets to emerge in decades, and current regulatory hurdles have created an early-stage funding gap for companies uniquely poised for considerable growth. We believe that addressing this funding gap will be a key catalyst for rapid market expansion. For our latest fund, we have partnered with Ambria Capital, a high-performance team focused on bringing the best mental health and technology innovations to market. Their in-depth industry expertise and relationships will prove vital to the success of Phyto IV." "We are seeing an increased focus on mental health and well-being among our peers and the broader public," added Cody Shandraw, Managing Partner. "As early pioneers in the psychedelics space, we are naturally excited for the tremendous growth potential, but more importantly, we are grateful to be playing a role in the development of new forms of medicine with real promise to benefit people's lives. As more people begin to realize the possibilities within neurowellness, we believe awareness will continue to swell, driving normalization and further industry growth." Amid growing awareness of the potential for psychedelic treatments for common mental health disorders, the U.S. FDA has authorized over 100 ongoing human clinical trials and has already granted breakthrough therapy designations for MDMA and psilocybin compounds, expediting their development and review due to the potential for substantial improvements over currently available therapies. As research accelerates, stigmas are being debunked and new innovations are developing an industry with a clear path to commercialization. The U.S. psychedelic drugs market is projected to reach nearly $7 billion by 2027, according to Data Bridge Market Research. "We are seeing emerging companies developing specific solutions for an industry in its infancy, in a market primed for explosive growth," continued Schnurmacher. "We are early, perhaps very early, but we believe the neurowellness space may develop and unfold much quicker than the cannabis market. We estimate that some of our target companies have a real chance of becoming industry leaders in the next few years." This is not an offer to sell any securities. Offering by private placement memorandum available upon request to accredited investors. SOURCE Phyto Partners

Ambria Capital Investments

5 Investments

Ambria Capital has made 5 investments. Their latest investment was in Clairvoyant Therapeutics as part of their Seed VC on November 11, 2021.

CBI Logo

Ambria Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/30/2021

Seed VC

Clairvoyant Therapeutics

$2.34M

Yes

Iter Investments, Negev Capital, and Undisclosed Investors

2

10/27/2021

Seed VC

Subscribe to see more

Subscribe to see more

10

6/29/2021

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

6/16/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2021

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/30/2021

10/27/2021

6/29/2021

6/16/2021

3/3/2021

Round

Seed VC

Seed VC

Seed VC

Series A

Convertible Note

Company

Clairvoyant Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.34M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Iter Investments, Negev Capital, and Undisclosed Investors

Sources

2

10

10

10

10

Ambria Capital Portfolio Exits

1 Portfolio Exit

Ambria Capital has 1 portfolio exit. Their latest portfolio exit was PsyTech Global on July 13, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/13/2021

Acquired

$99M

1

Date

7/13/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.